Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial
Jordi Bruix, Tadatoshi Takayama, Vincenzo Mazzaferro, Gar-Yang Chau, Jiamei Yang, Masatoshi Kudo, Jianqiang Cai, Ronnie T.P. Poon, Kwang–Hyub Han, Won Young Tak, Han Chu Lee, Tianqiang Song, Sasan Roayaie, Luigi Bolondi, Kwan Sik Lee, Masatoshi Makuuchi, Fabrício Henrique Pereira De Souza, Marie-Aude Le Berre, Gerold Meinhardt, Josep M. Llovet (2015). Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet Oncology, 16(13), pp. 1344-1354, DOI: 10.1016/s1470-2045(15)00198-9.
Article363 days agoSorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial
Riccardo Lencioni, Josep M. Llovet, Guohong Han, Won Young Tak, Jiamei Yang, Alfredo Guglielmi, Seung Woon Paik, María Reig, Do Young Kim, Gar-Yang Chau, Angelo Luca, L Ruíz del Arbol, Marie-Aude LeBerre, Woody Niu, Kate Nicholson, Gerold Meinhardt, Jordi Bruix (2016). Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial. Journal of Hepatology, 64(5), pp. 1090-1098, DOI: 10.1016/j.jhep.2016.01.012.
Article363 days agoBrivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study
Josep M. Llovet, Thomas Decaens, Jean‐Luc Raoul, Éveline Boucher, Masatoshi Kudo, Charissa Chang, Yoon‐Koo Kang, Éric Assenat, Ho-Yeong Lim, Valérie Boige, Philippe Mathurin, Lætitia Fartoux, Deng‐Yn Lin, Jordi Bruix, Ronnie T.P. Poon, Morris Sherman, Jean–Frédéric Blanc, Richard S. Finn, Won Young Tak, Yee Chao, Rana Ezzeddine, David Liu, Ian Walters, Joong‐Won Park (2013). Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study. Journal of Clinical Oncology, 31(28), pp. 3509-3516, DOI: 10.1200/jco.2012.47.3009.
Article363 days agoSorafenib or placebo in combination with transarterial chemoembolization (TACE) with doxorubicin-eluting beads (DEBDOX) for intermediate-stage hepatocellular carcinoma (HCC): Phase II, randomized, double-blind SPACE trial.
Riccardo Lencioni, Josep M. Llovet, Guohong Han, Won Young Tak, Jiamei Yang, Marie-Aude LeBerre, Woody Niu, Kate Nicholson, Gerold Meinhardt, Jordi Bruix (2012). Sorafenib or placebo in combination with transarterial chemoembolization (TACE) with doxorubicin-eluting beads (DEBDOX) for intermediate-stage hepatocellular carcinoma (HCC): Phase II, randomized, double-blind SPACE trial.. Journal of Clinical Oncology, 30(4_suppl), pp. LBA154-LBA154, DOI: 10.1200/jco.2012.30.4_suppl.lba154.
Article363 days ago1398 BRIVANIB VERSUS PLACEBO IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC) WHO FAILED OR WERE INTOLERANT TO SORAFENIB: RESULTS FROM THE PHASE 3 BRISK-PS STUDY
Josep M. Llovet, Thomas Decaens, Jean‐Luc Raoul, Éveline Boucher, Masatoshi Kudo, Cheng‐Chen Chang, Yang Kang, Éric Assenat, Ho-Yeong Lim, Valérie Boige, Philippe Mathurin, Lætitia Fartoux, Derek Lin, Jordi Bruix, Rtp Poon, Morris Sherman, J.-F. Blanc, Richard S. Finn, Won Young Tak, You‐Chen Chao, Rana Ezzeddine, D. Liu, Ian Walters, J.-W. Park (2012). 1398 BRIVANIB VERSUS PLACEBO IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC) WHO FAILED OR WERE INTOLERANT TO SORAFENIB: RESULTS FROM THE PHASE 3 BRISK-PS STUDY. Journal of Hepatology, 56, pp. S549-S549, DOI: 10.1016/s0168-8278(12)61409-3.
Article363 days ago